[1]陆伦根.胆汁淤积性肝病临床和基础研究热点和难点.中华肝脏病杂志,2015,23(8):561-563. [2]Pant C, Jani B S, Desai M, et al. Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the nationwide inpatient sample 2002-2012. J Investig Med,2016,64(1):33. [3]O'Leary JG, Reddy KR, Garcia-Tsao G, et al. NACSELD acute-on-chronic liver failure (NACSELD‐ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology,2018,67(6):2367-2374. [4]陈小青,王迎春.肝内胆汁淤积性肝病的病因与治疗.实用肝脏病杂志,2018,21(2):163-165. [5]Williams GM, Duan JD, Iatropoulos MJ, et al. Sex differences in DNA damage produced by the carcinogen 2-acetylaminofluorene in cultured human hepatocytes compared to rat liver and cultured rat hepatocytes. Arch Toxicol,2016,90(2):427-432. [6]Ovadia C, Lovgren-Sandblom A, Edwards LA, et al. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. J Clin Apher,2018,33 (6):638-644. [7]Blaya D, Coll M, Rodrigotorres D, et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut,2016,65(9):1535-1545. [8]Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytok Growt Fact Rev,2015,26(1):25-33. [9]Taleb S, Tedgui A, Mallat Z. IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles. Arterioscler Thromb Vasc Biol,2015,35(2):258-264. [10]Zhao Y, Li Y, Wang J, et al. Fluoride induces apoptosis and autophagy through the IL-17 signaling pathway in mice hepatocytes. Arch Toxicol,2018,92 (11):3277-3289. [11]Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer,2015,112(9):1501-1509. [12]Naradikian MS, Myles A, Beiting DP, et al. Cutting edge: IL-4, IL-21, and IFN-γ interact to govern T-bet and CD11c expression in TLR-activated B Cells. J Immunol,2016,197(4):1023-1028. [13]赵凯,商庆华,宋文刚.γ-干扰素诱生蛋白10与肝病关系研究进展.实用肝脏病杂志,2017,20(1):120-123. [14]Yuhai G, Zhen Z. Significance of the changes occurring in the levels of interleukins, SOD and MDA in rat pulmonary tissue following exposure to different altitudes and exposure times. Exp Ther Med,2015,10(3):915-920. [15]Su X, He Y, Yang W, et al. Effect of Dan Hong injection on PON1, SOD activity and MDA levels in elderly patients with coronary heart disease. Int J Clin Exp Med,2014,7(12):5886-5889. [16]Huang XF, Zhao WY, Huang WD. FXR and liver carcinogenesis. Acta Pharmacol Sin,2015,36(1):37. [17]Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet,2015,385(9972):956-965. [18]van Golen RF, Olthof PB, Lionarons DA, et al. FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis. Sci Rep,2018,8(1):16529. [19]Hu YB, Liu XY, Zhan W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Des Devel Ther,2018,18(12):2213-2221. [20]丁艳,熊小丽,赵雷,等.法尼醇X受体在大鼠急性淤胆型肝炎中的作用.中华肝脏病杂志,2016,24(6):441-445. |